GWSA
VRTX icon

Global Wealth Strategies & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Global Wealth Strategies & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11
Closed -$4.31K – 602
2025
Q3 		$4.31K Hold
11
– – ﹤0.01% 348
2025
Q2 		$4.9K Hold
11
– – ﹤0.01% 265
2025
Q1 		$5.33K Hold
11
– – ﹤0.01% 314
2024
Q4 		$4.43K Hold
11
– – ﹤0.01% 272
2024
Q3 		$5.12K Buy
+11
New +$5.28K ﹤0.01% 239

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Global Wealth Strategies & Associates's VRTX Position: Q4 2025 in Review

Global Wealth Strategies & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 11 shares — an estimated $4.31K sold.

Global Wealth Strategies & Associates first reported a position in VRTX in Q3 2024 and held it in 5 quarters. The position peaked at $5.33K in Q1 2025. 1,669 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Global Wealth Strategies & Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 11 Vertex Pharmaceuticals shares in Q4 2025, an estimated $4.31K.
  • Global Wealth Strategies & Associates first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Global Wealth Strategies & Associates's Vertex Pharmaceuticals position peaked at $5.33K in Q1 2025.
  • 1,669 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Global Wealth Strategies & Associates's 13F filing for Q4 2025, filed 2 Jan 2026.